Chemistry:Suraxavir marboxil
From HandWiki
Short description: Investigational drug
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C29H25F2N3O7S |
| Molar mass | 597.59 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Suraxavir marboxil is an investigational new drug that is being evaluated by Jiangxi Qingfeng Pharmaceutical for the treatment of influenza virus infection.[1] It is an inhibitor or the cap-dependent RNA-dependent RNA polymerase of the influenza A and B virus.[1][2][3][4]
Suraxavir marboxil is a prodrug that is metabolized to the active drug suraxavir (GP1707D07).[5]
References
- ↑ 1.0 1.1 "Suraxavir marboxil". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800062130.
- ↑ "A phase I study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of suraxavir marboxil: a novel oral antiviral for influenza". Antimicrobial Agents and Chemotherapy 70 (5): e0166825. May 2026. doi:10.1128/aac.01668-25. PMID 41870058.
- ↑ "Anti-influenza drugs targeting trimeric RNA polymerase complex: From development to clinics". Acta Pharmaceutica Sinica. B 16 (2): 728–745. February 2026. doi:10.1016/j.apsb.2025.11.033. PMID 41685158.
- ↑ "Antiviral strategies against H5N1: current options and emerging therapeutics". Infection 54 (1): 25–39. February 2026. doi:10.1007/s15010-025-02657-y. PMID 41105303.
- ↑ "Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism". Frontiers in Pharmacology 15. 2024. doi:10.3389/fphar.2024.1505557. PMID 40291342.
 |  |
